Novavax (NVAX) to Release Earnings on Wednesday

Key Points

• Novavax will release Q1 2026 results before the market opens on May 6, 2026; analysts expect ($0.25) EPS and $78.32 million in revenue, with the earnings call scheduled for 8:30 AM ET.
• In the prior quarter Novavax beat expectations, reporting $0.11 EPS (consensus −$0.66) and $136.4 million in revenue, a 66.6% year‑over‑year increase.
• The stock has about a $1.32 billion market cap and a P/E of 3.34; Wall Street’s consensus rating is Hold with an average target of $11.88, and institutions own roughly 53% of the shares.

Novavax (NASDAQ:NVAX - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Novavax to post earnings of ($0.25) per share and revenue of $78.3220 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:30 AM ET.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of ($0.66) by $0.77. The firm had revenue of $136.40 million during the quarter, compared to analysts' expectations of $90.26 million. Novavax had a net margin of 39.19% and a negative return on equity of 673.17%. The firm's revenue for the quarter was up 66.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.51) earnings per share. On average, analysts expect Novavax to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Novavax Stock Performance

Shares of NASDAQ:NVAX opened at $8.04 on Friday. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of 3.34 and a beta of 2.37. Novavax has a 1-year low of $5.80 and a 1-year high of $11.97. The company has a 50 day moving average price of $9.08 and a 200 day moving average price of $8.20.

Institutional Investors Weigh In On Novavax

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NVAX. Quarry LP purchased a new stake in Novavax in the 3rd quarter worth approximately $33,000. State of Wyoming purchased a new stake in Novavax in the 2nd quarter worth approximately $52,000. Danske Bank A S purchased a new stake in Novavax in the 3rd quarter worth approximately $64,000. Dimensional Fund Advisors LP purchased a new stake in Novavax in the 4th quarter worth approximately $75,000. Finally, Williams Jones Wealth Management LLC. purchased a new stake in Novavax in the 4th quarter worth approximately $77,000. Hedge funds and other institutional investors own 53.04% of the company's stock.

Wall Street Analysts Forecast Growth

NVAX has been the subject of a number of recent analyst reports. B. Riley Financial reaffirmed a "buy" rating on shares of Novavax in a research note on Thursday, April 9th. Weiss Ratings raised shares of Novavax from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, March 12th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Novavax in a research note on Thursday, March 12th. BTIG Research reaffirmed a "buy" rating and issued a $19.00 price objective on shares of Novavax in a research note on Tuesday, January 20th. Finally, Wall Street Zen raised shares of Novavax from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $11.88.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company's lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.